Difamilast is a medicine used to treat mild to moderate eczema (atopic dermatitis). It's an ointment you rub onto the itchy, red patches of skin. It works by calming the inflammation in the skin.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Difamilast, sold in the US as Adquey, is a prescription ointment for mild to moderate atopic dermatitis, the most common type of eczema. It is approved for adults and children 2 years and older. Its safety and effectiveness have not been established in children younger than 2. Difamilast is a nonsteroid anti-inflammatory medicine. It was approved in the US in 2026 and had already been used in Japan, where eczema guidelines list it alongside steroid creams and tacrolimus ointment as a skin treatment for calming flares. In the US it joins a range of prescription options for mild to moderate eczema, including topical corticosteroids, topical calcineurin inhibitors and several newer creams. Choosing between them depends on where the rash is, the person's age, past response and how a treatment feels on the skin.
Eczema involves an overactive immune response in the skin. Immune cells release signaling chemicals that drive the redness, swelling and itch. Difamilast belongs to a group of medicines called phosphodiesterase 4 (PDE4) inhibitors. PDE4 is an enzyme inside cells that breaks down a messenger molecule called cyclic AMP (cyclic adenosine monophosphate). By blocking PDE4, difamilast lets cyclic AMP build up, which in turn reduces the production of several of those inflammatory signals. The manufacturer notes that exactly how this translates into clearer skin is not fully understood. Used on limited areas of skin, very little of the medicine reaches the bloodstream.
Adquey comes as a 1% ointment. A thin layer is applied to the affected areas twice a day and rubbed in until it can no longer be seen. Wash your hands afterward, and anyone who applies it for someone else, such as a parent treating a child, should wash their hands too. It is for use on the skin only, not in or near the eyes, mouth or vagina. Do not apply it to skin that looks infected, meaning areas that are red, warm, swollen or painful in a way that differs from the usual eczema; have those areas checked instead. Store the tube at room temperature, closed tightly and away from heat and sunlight.
In clinical trials, difamilast was generally well tolerated. The most commonly reported problem was nasopharyngitis, meaning cold-like symptoms such as a sore or swollen nose and throat, which occurred in about 6% of people using difamilast compared with 4% using a plain ointment. Less often, people had reactions where the ointment was applied: inflamed hair follicles, a new rash or skin irritation, and molluscum contagiosum (a common viral skin infection that causes small bumps). During longer use, some people stopped treatment because of pain, itching, blisters, redness or burning at the application site, and swelling has been reported since approval. If the treated skin becomes more irritated, blisters or burns, or the rash spreads rather than settling, contact the prescriber.
Difamilast has no listed contraindications and no boxed warning. No studies have tested how the ointment interacts with other medicines, so tell the prescriber and pharmacist about all prescription and over-the-counter medicines, vitamins and herbal supplements, and about any other creams used on the same skin. There is not enough information to know whether difamilast affects a pregnancy, so anyone who is pregnant or planning a pregnancy should discuss it with the prescriber. It is not known whether it passes into human breast milk. People who are breastfeeding should not apply it to the nipple or the darker skin around it, and should keep a baby's skin from touching treated areas. Very few people aged 65 and older were included in the studies.
Difamilast is meant to calm eczema gradually rather than give instant relief. In the trials, results were judged after four weeks of twice-daily use, using a doctor's 0 to 4 rating of overall eczema severity. Reaching clear or almost clear skin, with at least a two-step improvement, was the measure of success. Between about 1 in 5 and nearly half of people using difamilast reached that point, depending on the study, compared with roughly 1 in 30 to 1 in 5 using the plain ointment base. That means many people improve without fully clearing. Most participants were studied in Japan, and none of the trials compared difamilast directly with steroid creams or other eczema medicines. Atopic dermatitis is often long-lasting and tends to flare and settle over time, so the medicine is one part of ongoing care alongside moisturizing and avoiding personal triggers. Some people used it for up to a year in longer studies. If the skin has not improved after several weeks, or flares keep coming back, the prescriber may adjust the plan or suggest a different treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Adquey (Difamilast), what you've noticed, or ask the community a question.